Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gtf2ird1Tg(Alb1-Myc)166.8Sst mutation
(0 available);
any
Gtf2ird1 mutation
(358 available)
Tg(Alb-E2F1)8Sst mutation
(0 available)
|
|
|
neoplasm
|
|
• mutants develop diffuse liver dysplasia by 3 months of age
|
|
|
• 22% of mutants develop hepatocellular carcinomas by 6 months of age and by 9 months of age, 100% of mutants show hepatocellular carcinomas, indicating that tumors are more severe and arise faster than in single transgenic mice
• tumors are predominantly moderately well differentiated with trabecular, solid and trabecular/pseudoglandular pattern
|
liver/biliary system
|
|
• mutants develop diffuse liver dysplasia by 3 months of age
|
|
|
• 22% of mutants develop hepatocellular carcinomas by 6 months of age and by 9 months of age, 100% of mutants show hepatocellular carcinomas, indicating that tumors are more severe and arise faster than in single transgenic mice
• tumors are predominantly moderately well differentiated with trabecular, solid and trabecular/pseudoglandular pattern
|
Allelic
Composition |
Tg(Alb-E2F1)8Sst/0
|
|
Genetic
Background |
involves: C57BL/6J * CBA/J |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
neoplasm
|
|
• liver tumor progression begins with preneoplastic foci adjacent to portal tracts and pericentral large cell dysplasia at 2 months of age, followed by an abrupt increase in the number of neoplastic nodules or adenomas from 4-6 months onward, with 100% incidence by 10 months of age, and finally some adenomas show evidence of malignant transformation into trabecular hepatocellular carcinoma
(J:65354)
|
|
|
• mice show features of malignant transformation in some of the adenomas by 10 months of age
(J:65354)
• 60% of mutants develop hepatocellular carcinoma by 12 months of age
(J:101128)
• tumors are predominantly well-differentiated
(J:101128)
|
|
|
• 100% incidence of adenomas by 10-12 months of age
|
liver/biliary system
|
|
• livers show an increase in cell proliferation; at one month of age, the proliferation index is increased about 1.4-fold compared to wild-type, then proliferation decreases at 2 months of age so it is 2-fold lower than at 1 months of age but it is 6-fold higher than in wild-type livers at this time
|
|
|
• macrovesicular hepatic steatosis is first seen in livers at 6-8 months of age and by 10-12 months of age, 60% of mutants develop prominent fatty change
|
|
|
• liver tumor progression begins with preneoplastic foci adjacent to portal tracts and pericentral large cell dysplasia at 2 months of age, followed by an abrupt increase in the number of neoplastic nodules or adenomas from 4-6 months onward, with 100% incidence by 10 months of age, and finally some adenomas show evidence of malignant transformation into trabecular hepatocellular carcinoma
(J:65354)
|
|
|
• mice show features of malignant transformation in some of the adenomas by 10 months of age
(J:65354)
• 60% of mutants develop hepatocellular carcinoma by 12 months of age
(J:101128)
• tumors are predominantly well-differentiated
(J:101128)
|
|
|
• 100% incidence of adenomas by 10-12 months of age
|
cellular
|
|
• livers show an increase in cell proliferation; at one month of age, the proliferation index is increased about 1.4-fold compared to wild-type, then proliferation decreases at 2 months of age so it is 2-fold lower than at 1 months of age but it is 6-fold higher than in wild-type livers at this time
|
Analysis Tools